Trial Profile
NN1250-3579: A 52-week Randomised, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA and Insulin Glargine, Both Injected Once Daily in Cmbination With Oral Anti-diabetic Drugs (OAD), in Subjects With Type 2 Diabetes Mellitus Currently Treated With OAD(s) and Qualifying for More Intensified Treatment
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Jan 2022
Price :
$35
*
At a glance
- Drugs Insulin degludec (Primary) ; Insulin glargine
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms BEGIN
- Sponsors Novo Nordisk
- 05 Oct 2012 Primary endpoint results after 52 weeks presented at the 48th Annual Meeting of the European Association for the Study of Diabetes.
- 12 Jun 2012 Effects of treatment on health status and efficacy results of the 26-week study presented at the 72nd Annual Scientific Sessions of the American Diabetes Association.
- 09 Jun 2012 Primary endpoint 'Proportion-of-glycosylated-haemoglobin' has been met.